Bristol-Myers Squibb confirms sale of stake in Sino-US Shanghai Squibb Pharmaceutical Co., Ltd
2025-09-15 13:15:47
On September 15th, Bristol-Myers Squibb confirmed that the company has signed an agreement to sell its 60% stake in Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. Bristol-Myers Squibb said that the company's strong commitment to the Chinese market remains unchanged, and will continue to invest in the Chinese market under the guidance of the company's "China 2030 Strategy". In the future, it will continue to focus on accelerating the introduction of innovative cutting-edge therapies in a wide range of disease fields, and make every effort to improve drug access.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
